No Data
No Data
No Data
Mallinckrodt Presents Data on TERLIVAZ (Terlipressin) for Injection in Patients With Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week (DDW)
– Two poster presentations of Mallinckrodt's research for adults with HRS with rapid reduction in kidney function1 provide further insight into treatment with TERLIVAZ for appropriate patients – DUBL
10-Q: Quarterly report
Press Release: Mallinckrodt Plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance PR Newswire DUBLIN, March 26, 2024 Exceeds High End of Guidance Range on Net Sales and Adju
Press Release: Mallinckrodt Plc Reports Fourth -11-
Property, plant and equipment, net 321.7 457.6 Intangible assets, net 608.4 2,843.8 Deferred income taxes
Mallinckrodt Plc: Expects to Incur Pre-Tax Charges, Exclusive of Impairments, of Approximately $15 Million, Plans to Recognize in 1Q 2024 and Remaining Amount Over FY24 and First Fiscal Quarter 2025
Mallinckrodt Plc: Expects to Incur Pre-Tax Charges, Exclusive of Impairments, of Approximately $15 Million, Plans to Recognize in 1Q 2024 and Remaining Amount Over FY24 and First Fiscal Quarter 2025
Mallinckrodt Plc: Evaluating Next Steps With Respect to StrataGraft, Which Could Include Pursuing a Sale, Out-License or Other Strategic Arrangement
Mallinckrodt Plc: Evaluating Next Steps With Respect to StrataGraft, Which Could Include Pursuing a Sale, Out-License or Other Strategic Arrangement
No Data